Pioneering Medical Innovations
Imperative Care expanded its Symphony thrombectomy portfolio with a design purpose-built for treating venous thrombosis.
Instylla submitted the final module of its premarket approval application for the Embrace Hydrogel Embolic System, including clinical study results supporting the hypervascular tumor embolization indication.
Axtria launched Axtria Rapid CSR, a generative-AI approach to clinical study report development designed to cut report generation time by 30–50% for most large Phase III trials.
Instylla announced FDA 510(k) clearance of the Tembo Embolic System, expanding its portfolio of solutions for peripheral vascular embolization.
The FDA granted 510(k) clearance for the Zoom System, the first comprehensive stroke thrombectomy system to include large-bore .088-inch catheters indicated for both access and aspiration, supported by final Imperative Trial data.
Ocular reported Q3 2024 results, highlighting progress in the SOL-1 and SOL-R registrational trials of AXPAXLI in wet AMD and a cash balance of $427.2 million expected to fund operations into 2028.
The company completed the initial closing of a Series E round of up to $150 million and named Shacey Petrovic Vice Chair of its Board of Directors.
Imperative Care shared results from its pivotal Imperative Trial of the Zoom Reperfusion System in ischemic stroke, presented in connection with the SNIS annual meeting.
New technology offered in three unique shapes expands the company’s comprehensive stroke system, allowing physicians to achieve fast and consistent
Award Honors Top Executives Fueling Innovation and Impact in the Life Sciences Industry Axtria, a global leader in cloud software